Natera, Inc. is a U.S.-based molecular diagnostics company specializing in cell-free DNA (cfDNA) analysis. It develops and commercializes tests for oncology, women’s health, and organ health that support risk assessment, disease monitoring, and clinical decision-making.
Core products include Signatera, a personalized, tumor-informed circulating tumor DNA assay used to detect minimal residual disease and monitor cancer recurrence; Panorama, a noninvasive prenatal test; Horizon, a carrier screening panel; and Prospera, a cfDNA test for transplant rejection assessment. Natera applies next-generation sequencing and proprietary bioinformatics to analyze cfDNA from blood, and collaborates with hospitals, laboratories, and biopharma partners for clinical use, research, and companion diagnostic development.